한글목차

자간전증 치료제 시장 규모는 최근 급성장하고 있습니다. 2025년 13억 7,000만 달러에서 2026년에는 15억 2,000만 달러에 이르고, CAGR 10.6%의 성장이 전망되고 있습니다. 지금까지의 성장은 자간전증 관리에 대한 인식 부족, 기존 치료법에 대한 의존도, 첨단 모니터링 기술 부족, 병원 인프라 미비, 임산부용 의약품에 대한 투자 부족 등이 원인으로 꼽힙니다.

향후 몇 년간 자간전증 치료제 시장 규모는 급성장이 전망됩니다. 2030년에는 23억 7,000만 달러에 이르고, CAGR은 11.8%를 나타낼 전망입니다. 예측 기간 동안의 성장은 약물 제제의 발전, 헬스케어 인프라 확충, 외래 임산부 케어 수요 증가, 디지털 헬스 솔루션의 통합, 임신 합병증에 대한 정밀의료 연구개발(R&:D) 증가에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 임산부 자간전증 발생률 증가, 신규 항고혈압제 개발, 모체 및 태아 건강 모니터링에 대한 관심 증가, 병원 약국 및 전문 클리닉에서의 유통 확대, 중증 환자에 대한 병용요법 도입 등을 꼽을 수 있습니다.

임산부의 당뇨병 유병률 증가는 향후 자간전증 치료제 시장 확대에 기여할 것으로 예측됩니다. 당뇨병은 혈당 상승을 특징으로 하는 만성 대사성 질환입니다. 자간전증은 고혈압과 장기 손상을 동반하는 위험한 임신 합병증입니다. 자간전증 치료제인 메트포르민은 조기 자간전증 임산부에게 흔히 처방됩니다. 예를 들어, 영국 정부 기관인 국민보건서비스(NHS)에 따르면, 2024년 6월 기준 2023년 영국에서 54만 9,000명 이상이 새롭게 2형 당뇨병 발병 위험이 있는 것으로 확인되었습니다. 이로써 주치의에 등록된 비당뇨병성 고혈당(전당뇨병) 환자 수는 총 361만 5,330명에 달할 전망입니다. 이는 2022년 306만 5,825명에 비해 큰 폭으로 증가한 것으로, 약 20%의 상승률을 보이고 있습니다. 따라서 임산부의 당뇨병 환자 증가는 자간전증 치료제 시장을 견인할 것입니다.

자간전증 치료제 시장의 주요 기업들은 혁신적인 작용기전을 통해 미충족 수요를 충족시키기 위해 소간섭성 RNA(siRNA) 치료를 포함한 첨단 치료제 개발에 우선순위를 두고 있습니다. siRNA 임상시험용 의약품은 질병을 촉진하는 특정 유전자를 침묵시키거나 억제하도록 설계된 약물 범주로, 정밀한 치료 전략을 제공합니다. 예를 들어, 2023년 3월 미국 바이오 제약기업인 코만치 바이오파마는 자간전증 치료용 siRNA 치료제 'CBP-4888'에 대해 미국 식품의약국(FDA)이 임상시험계획(IND)을 승인했다고 발표했습니다. CBP-4888은 피하로 투여되며, 태반에서 가용성 Fms 유사 티로신 키나아제-1(sFLT1)의 생성을 억제합니다. 태반에서 과잉 생산된 sFLT1 단백질은 모체의 혈류로 순환하여 자간전증을 유발합니다. CBP-4888은 자간전증(자간전증)의 증상인 고혈압, 장기 손상 등의 증상 완화에 기여하여 보다 안전한 임신 기간 연장을 가능하게 할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Preeclampsia medications are drugs used to manage and treat preeclampsia, a dangerous pregnancy complication involving high blood pressure and organ damage, such as to the liver and kidneys. Healthcare professionals typically prescribe these drugs to pregnant women with preeclampsia to reduce blood pressure and avoid additional complications.

The primary categories of preeclampsia medications target mild preeclampsia and severe preeclampsia. Mild preeclampsia represents a medical condition affecting certain pregnant women, typically arising after the 20th week of gestation. These drugs support diverse treatments, including blood pressure-lowering agents, corticosteroids, and anticonvulsants, delivered via routes like oral, parenteral, and additional methods. They are accessible through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and more, and serve multiple end-users, including hospitals, specialty clinics, diagnostic centers, and others.

Tariffs have impacted the preeclampsia drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized drug formulations, thereby raising production costs for manufacturers. The hospital pharmacy and severe preeclampsia medication segments, particularly in North America and Europe, are most affected due to reliance on imported components. Some positive impacts include incentivizing local production and encouraging manufacturers to invest in domestic drug development and supply chain diversification, which may lead to long-term cost optimization and innovation.

The preeclampsia drugs market research report is one of a series of new reports from The Business Research Company that provides preeclampsia drugs market statistics, including preeclampsia drugs industry global market size, regional shares, competitors with a preeclampsia drugs market share, detailed preeclampsia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the preeclampsia drugs industry. This preeclampsia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.37 billion in 2025 to $1.52 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to limited awareness of preeclampsia management, reliance on traditional therapies, lack of advanced monitoring technologies, insufficient hospital infrastructure, low investment in maternal health drugs.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in drug formulations, expansion of healthcare infrastructure, rising demand for outpatient maternal care, integration of digital health solutions, increased R&D in precision medicine for pregnancy complications. Major trends in the forecast period include rising incidence of preeclampsia among pregnant women, development of novel antihypertensive drugs, increased focus on maternal and fetal health monitoring, growth of hospital pharmacy and specialty clinics distribution, adoption of combination therapies for severe cases.

The increasing prevalence of diabetes in pregnant women is anticipated to boost the preeclampsia drug market in the future. Diabetes is a chronic metabolic disorder marked by elevated blood glucose (or blood sugar) levels. Preeclampsia is a dangerous pregnancy complication involving high blood pressure and organ damage. Metformin, a treatment for preeclampsia, is commonly prescribed for pregnant women with preterm preeclampsia. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing number of diabetes cases among pregnant women will fuel the preeclampsia drug market.

Major companies in the preeclampsia medicine market are prioritizing the development of advanced therapies, including small interfering RNA (siRNA) treatments, to meet critical unmet medical needs through innovative mechanisms of action. siRNA investigational therapies represent a category of drugs engineered to silence or inhibit specific genes that drive disease, providing a precise treatment strategy. For example, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had cleared an investigational new drug (IND) application for CBP-4888, their proprietary siRNA therapy for preeclampsia. CBP-4888 is administered subcutaneously and suppresses the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's excessive production of the sFLT1 protein, which circulates into the mother's bloodstream, drives preeclampsia. CBP-4888 helps relieve preeclampsia symptoms like high blood pressure and organ damage, potentially enabling safer prolongation of pregnancy.

In March 2024, ASKA Pharmaceutical Co., Ltd., a Japan-based pharmaceutical firm, collaborated with Red Arrow Therapeutics, Inc., to co-develop a new preeclampsia treatment. This alliance draws on ASKA's maternal health knowledge and Red Arrow's pH-responsive nanomedicine platform to create a more precise, safer, and potent option for preeclampsia patients. Red Arrow Therapeutics Inc. is a US biotechnology company specializing in innovative cancer therapies.

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the preeclampsia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preeclampsia Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses preeclampsia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preeclampsia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preeclampsia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Mild Preeclampsia; Severe Preeclampsia
• 2) By Treatment: Medication to Lower Hypertension (B.P); Corticosteroids; Anticonvulsants Medication
• 3) By Route of Administration: Oral; Parenteral; Other Route of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users
• Subsegments:
• 1) By Mild Preeclampsia: Blood Pressure Management
• 2) By Severe Preeclampsia: Antihypertensive Medications; Magnesium Sulfate Therapy
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Johnson & Johnson Co; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline PLC; Takeda Pharmaceuticals Company Limited; Eli Lilly and Company; Boehringer Ingelheim Group; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Baxter International Inc.; Otsuka Pharmaceutical Co. Ltd.; Mallinckrodt Pharmaceuticals Limited; Union Chimique Belge SA; Kyowa Kirin Co Ltd; Comanche Biopharma Corp
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Preeclampsia Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Preeclampsia Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Preeclampsia Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Preeclampsia Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Incidence Of Preeclampsia Among Pregnant Women
  • 4.2.2 Development Of Novel Antihypertensive Drugs
  • 4.2.3 Increased Focus On Maternal And Fetal Health Monitoring
  • 4.2.4 Growth Of Hospital Pharmacy And Specialty Clinics Distribution
  • 4.2.5 Adoption Of Combination Therapies For Severe Cases

5. Preeclampsia Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Diagnostic Centers
• 5.4 Retail Pharmacies
• 5.5 Online Pharmacies

6. Preeclampsia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Preeclampsia Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Preeclampsia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Preeclampsia Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Preeclampsia Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Preeclampsia Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Preeclampsia Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Preeclampsia Drugs Market Segmentation

• 9.1. Global Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Mild Preeclampsia, Severe Preeclampsia
• 9.2. Global Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
• 9.3. Global Preeclampsia Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Route of Administration
• 9.4. Global Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
• 9.5. Global Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
• 9.6. Global Preeclampsia Drugs Market, Sub-Segmentation Of Mild Preeclampsia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Blood Pressure Management
• 9.7. Global Preeclampsia Drugs Market, Sub-Segmentation Of Severe Preeclampsia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antihypertensive Medications, Magnesium Sulfate Therapy

10. Preeclampsia Drugs Market Regional And Country Analysis

• 10.1. Global Preeclampsia Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Preeclampsia Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Preeclampsia Drugs Market

• 11.1. Asia-Pacific Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Preeclampsia Drugs Market

• 12.1. China Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Preeclampsia Drugs Market

• 13.1. India Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Preeclampsia Drugs Market

• 14.1. Japan Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Preeclampsia Drugs Market

• 15.1. Australia Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Preeclampsia Drugs Market

• 16.1. Indonesia Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Preeclampsia Drugs Market

• 17.1. South Korea Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Preeclampsia Drugs Market

• 18.1. Taiwan Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Preeclampsia Drugs Market

• 19.1. South East Asia Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Preeclampsia Drugs Market

• 20.1. Western Europe Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Preeclampsia Drugs Market

• 21.1. UK Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Preeclampsia Drugs Market

• 22.1. Germany Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Preeclampsia Drugs Market

• 23.1. France Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Preeclampsia Drugs Market

• 24.1. Italy Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Preeclampsia Drugs Market

• 25.1. Spain Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Preeclampsia Drugs Market

• 26.1. Eastern Europe Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Preeclampsia Drugs Market

• 27.1. Russia Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Preeclampsia Drugs Market

• 28.1. North America Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Preeclampsia Drugs Market

• 29.1. USA Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Preeclampsia Drugs Market

• 30.1. Canada Preeclampsia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Preeclampsia Drugs Market

• 31.1. South America Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Preeclampsia Drugs Market

• 32.1. Brazil Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Preeclampsia Drugs Market

• 33.1. Middle East Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Preeclampsia Drugs Market

• 34.1. Africa Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Preeclampsia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Preeclampsia Drugs Market Regulatory and Investment Landscape

36. Preeclampsia Drugs Market Competitive Landscape And Company Profiles

• 36.1. Preeclampsia Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Preeclampsia Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Preeclampsia Drugs Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Preeclampsia Drugs Market Other Major And Innovative Companies

• Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

38. Global Preeclampsia Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Preeclampsia Drugs Market

40. Preeclampsia Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Preeclampsia Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Preeclampsia Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Preeclampsia Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer